{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"AAV9 Gene Replacement Therapy: The Quiet Hope for Ultra-Rare UBA5 Disorder","author_name":"techandbusiness.org · Tech & Business","thumbnail_url":"https://techandbusiness.org/api/og/newswire/HdB4jQRO2sDquJ8J0RaEvd","thumbnail_width":1200,"thumbnail_height":630,"width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Tech & Business</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/HdB4jQRO2sDquJ8J0RaEvd\" style=\"color:#fff;text-decoration:none;\">AAV9 Gene Replacement Therapy: The Quiet Hope for Ultra-Rare UBA5 Disorder</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">Genezen and the Raiden Science Foundation announced on August 3, 2026, a manufacturing partnership to advance an AAV9 gene replacement therapy toward a first-in-human clinical trial for UBA5 disorder....</p>\n    </blockquote>"}